Insitro, a biotech company founded in 2018 by Daphne Koller, has raised over $643 million in venture capital and has more than 260 employees. The company has been quiet despite being well-funded and having access to significant resources. The company’s goal and focus are not specified, leaving many questioning what exactly Koller is building. This has piqued curiosity and drawn attention to the secretive nature of the company despite its success and substantial financial backing.
Source link
Insitro, AI biotech unicorn, brings cash, new research to JPM 2024
